BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Today 7:30 EDT

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗

Performance

52-Week Range 29.2% below 52-week high

66.14

52.7552W Low 93.4252W High

1 Week 3.7% below 1-week high

64.361W Low 68.681W High

BridgeBio Pharma, Inc. - Common Stock (BBIO) traded between $52.75 and $93.42 over the past 52 weeks and last traded at $66.14, 29.2% below its 52-week high. Over the past week it ranged between $64.36 and $68.68.

Past 12 Months

-0.7%

-11.6%

-14.9%

-8.5%

-15.5%

+21.1%

1W -$0.47

1M -$8.70

3M -$11.61

6M -$6.14

YTD -$12.09

1Y +$11.53

BBIO was +21.1% over the past year, -8.5% over six months, -15.5% year to date, -0.7% in the last week.

12 Months vs Market

BBIO

+21.1%

DIA

+9.7%

SPY

+15.4%

QQQ

+24.4%

IWM

+14.8%

Over the past 12 months BBIO returned +21.1% versus DIA (Dow) +9.7%, SPY (S&P 500) +15.4%, QQQ (Nasdaq 100) +24.4% and IWM (Russell 2000) +14.8%.

Volume & Liquidity 0.79× 3-mo avg

Today 2,168,494 3-mo avg 2.8M

3.1M

3.0M

2.8M

3.0M

YTD

2.9M

2.7M

BBIO most recently traded 2,168,494 shares against a 3-month average daily volume of 2.8M.

More News

September 26, 2026

Via MarketBeat

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

September 23, 2026

BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗

August 11, 2026

Via Chartmill

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 18, 2026

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

September 09, 2026

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

September 02, 2026

BridgeBio to Participate in September Investor Conferences

September 01, 2026

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

August 31, 2026

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

August 30, 2026

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

August 26, 2026

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

August 24, 2026

BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗

August 14, 2026

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

August 14, 2026

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

August 13, 2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 11, 2026

BridgeBio Pharma Q2 Earnings Call Highlights ↗

August 10, 2026

Via MarketBeat

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

August 10, 2026

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET

August 03, 2026

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗

August 02, 2026

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

July 22, 2026